DiscoverCME in Minutes: Education in Primary Care
CME in Minutes: Education in Primary Care
Claim Ownership

CME in Minutes: Education in Primary Care

Author: Answers in CME

Subscribed: 11Played: 22
Share
© 2022

Description

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Primary Care by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for the busy primary care providers to cover the diagnosis, treatment, follow-up, and clinical management of various disease states. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
236 Episodes
Reverse
Stella Lee, MD / Joseph K. Han, MD, FARS, FAAAAI - Spotlight on Emerging Biologics: Interpreting the Latest Efficacy and Safety Signals

Stella Lee, MD / Joseph K. Han, MD, FARS, FAAAAI - Spotlight on Emerging Biologics: Interpreting the Latest Efficacy and Safety Signals

2025-11-2730:23

Please visit answersincme.com/860/99066167-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the efficacy and safety of late-stage biologics in the treatment of CRSwNP. Upon completion of this activity, participants should be better able to: Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.
Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

2025-11-2521:11

Please visit answersincme.com/CAZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology answers the most commonly asked questions from clinicians about the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) with antibody–drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Identify patients with R/R DLBCL who may benefit from ADC therapy in the third-line or later setting; Interpret current evidence to inform selection of ADC therapies for patients with R/R DLBCL in the third-line or later setting; and Discuss strategies to optimize the use of ADC therapies for patients with R/R DLBCL, particularly in the community setting.
Luis Paz-Ares, MD, PhD / Lauren Averett Byers, MD - Shaping the Future of SCLC Treatment: Advancing Care Through Innovative Approaches

Luis Paz-Ares, MD, PhD / Lauren Averett Byers, MD - Shaping the Future of SCLC Treatment: Advancing Care Through Innovative Approaches

2025-11-2430:39

Please visit answersincme.com/860/97851223-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the latest advances in the treatment of small-cell lung cancer (SCLC), including both extensive-stage and limited-stage disease. Upon completion of this activity, participants should be better able to: Identify clinical factors that drive treatment decision-making for patients with SCLC; and Outline personalized treatment strategies to address key complexities affecting the optimal, real-world management of patients with SCLC.
Seenu M. Hariprasad, MD - A Closer Look at Emerging Anti-VEGF Therapies in Retinal Vein Occlusion Management: Practical Guidance for Specialists

Seenu M. Hariprasad, MD - A Closer Look at Emerging Anti-VEGF Therapies in Retinal Vein Occlusion Management: Practical Guidance for Specialists

2025-11-2116:10

Please visit answersincme.com/UPU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in managing patients with retinal vein occlusion (RVO) discusses the use of longer-acting anti-VEGF treatments for treating RVO. Upon completion of this activity, participants should be better able to: Explain the rationale for exploring longer-acting anti-VEGF treatment for patients with retinal vein occlusion (RVO); Differentiate the clinical profiles of available and emerging anti-VEGF treatments for macular edema following RVO, based on the latest evidence; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.
Doreen Addrizzo-Harris, MD - Relieving the Weight of Non-Cystic Fibrosis Bronchiectasis: Updated Strategies for an Evolving Landscape

Doreen Addrizzo-Harris, MD - Relieving the Weight of Non-Cystic Fibrosis Bronchiectasis: Updated Strategies for an Evolving Landscape

2025-11-2023:14

Please visit answersincme.com/KUS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary medicine discusses the treatment of patients with non–cystic fibrosis bronchiectasis (NCFB) using dipeptidyl peptidase 1 (DPP1) inhibitors. Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting neutrophilic inflammation in non–cystic fibrosis bronchiectasis (NCFB); Describe the clinical impact of DPP1 inhibitors for treating NCFB, in the context of conventional therapy; Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanomaApply strategies to enhance outcomes for patients with NCFB as the treatment landscape evolves; and Apply strategies to enhance outcomes for patients with NCFB as the treatment landscape evolves.
Terry Faleye, MPAS, PA-C / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Beyond Biologics for Psoriasis and PsA: TYK2 Inhibitors and Practical Considerations for Personalizing Care

Terry Faleye, MPAS, PA-C / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Beyond Biologics for Psoriasis and PsA: TYK2 Inhibitors and Practical Considerations for Personalizing Care

2025-11-1901:14:45

Please visit answersincme.com/860/100752367-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of psoriatic disease discuss challenges in treatment, emerging TYK2 inhibitor therapies, and evidence-based strategies to optimize patient care. Upon completion of this activity, participants should be better able to: Recognize how nurse practitioners and physician associates can help address barriers to care and enhance outcomes for patients with moderate to severe plaque psoriasis; Differentiate TYK2 signaling from JAK pathways and explain the relevance of these distinctions in clinical outcomes; Evaluate the impact of emerging data on TYK2 inhibitors in shaping therapeutic strategies for psoriatic disease; and Apply strategies for aligning TYK2 inhibitor therapy with patient needs and multidisciplinary care plans.
Stella Lee, MD / Kathleen Buchheit, MD - Advances in CRSwNP: Rethinking Biologics and Inflammation at the Source

Stella Lee, MD / Kathleen Buchheit, MD - Advances in CRSwNP: Rethinking Biologics and Inflammation at the Source

2025-11-1828:25

Please visit answersincme.com/860/99066167-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the ongoing burden of CRSwNP and the rationale for exploring novel biologics. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting epithelial cytokines to address unmet needs in the treatment of CRSwNP; and Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents.
Arielle Elkrief, MD - Navigating Neoadjuvant, Adjuvant, and Perioperative Immunotherapy in Resectable High-Risk Melanoma: Tailoring Care for Optimal Outcomes

Arielle Elkrief, MD - Navigating Neoadjuvant, Adjuvant, and Perioperative Immunotherapy in Resectable High-Risk Melanoma: Tailoring Care for Optimal Outcomes

2025-11-1817:08

Please visit answersincme.com/CAY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses how to optimize the use of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable high-risk melanoma. Upon completion of this activity, participants should be better able to: Recognize recurrence patterns in patients with resected high-risk melanoma and the importance of timely referral to improve recurrence-free survival; Evaluate the risk-benefit profiles of neoadjuvant, adjuvant, or perioperative immunotherapy in patients with resectable stage IIB/C and stage III/IV melanoma; and Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanoma.
Manjot K. Gill, MD, MS, Steven Ferrucci, OD, FAAO - Driving Diagnosis and Navigating the Role of Anti-VEGF Therapies in Managing Retinal Vein Occlusion

Manjot K. Gill, MD, MS, Steven Ferrucci, OD, FAAO - Driving Diagnosis and Navigating the Role of Anti-VEGF Therapies in Managing Retinal Vein Occlusion

2025-11-1316:29

Please visit answersincme.com/SYV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in retinal vein occlusion (RVO) discuss diagnosis and anti-VEGF treatment of the condition. Upon completion of this activity, participants should be better able to: Explain the rationale for exploring longer-acting anti-VEGF treatment for patients with RVO; Recognize the importance of early diagnosis to address the burden of RVO; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.
Linda Stein Gold, MD / April W. Armstrong, MD, MPH / Erin Boh, MD, PhD - Personalizing Psoriasis Care Across the Map: Navigating Regional Barriers to Integrating Oral Small Molecule Treatment for Moderate to Severe Disease

Linda Stein Gold, MD / April W. Armstrong, MD, MPH / Erin Boh, MD, PhD - Personalizing Psoriasis Care Across the Map: Navigating Regional Barriers to Integrating Oral Small Molecule Treatment for Moderate to Severe Disease

2025-11-0701:02:36

Please visit answersincme.com/860/99505211-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in psoriasis discuss real‑world strategies for using oral small molecules in moderate to severe disease. Upon completion of this activity, participants should be better able to: Identify patients with moderate to severe plaque psoriasis who would benefit from oral small molecule therapy; Differentiate the targets/mechanisms of action of available oral small molecule therapy for moderate to severe plaque psoriasis; and Integrate strategies to individualize oral small molecule therapy for moderate to severe plaque psoriasis, while balancing safety, considering regional barriers.
Asim V. Farooq, MD, Erica L. Mayer, MD, MPH - Ocular Safety in Breast Cancer Care: What Eye Clinicians Need to Know About Novel Oral Endocrine Therapies

Asim V. Farooq, MD, Erica L. Mayer, MD, MPH - Ocular Safety in Breast Cancer Care: What Eye Clinicians Need to Know About Novel Oral Endocrine Therapies

2025-11-0618:58

Please visit answersincme.com/XCG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. This educational activity brings together leading experts in ophthalmology and oncology to explore clinical strategies for managing ocular adverse events associated with a novel class of therapies for advanced breast cancer: the oral selective estrogen receptor degraders (SERDs). Faculty will share key insights and practical guidance on identifying and managing common ocular side effects—particularly photopsia and dry eye—with the goal of enhancing patient care and improving quality of life for individuals navigating survivorship with advanced breast cancer. Upon completion of this activity, participants should be better able to: Recognize the implications of using oral SERDs in HR-positive, HER2-negative breast cancer for ophthalmic practice; Describe the ocular toxicities associated with oral SERDs used in breast cancer treatment; and Apply multidisciplinary strategies to facilitate the detection and management of ocular toxicities in patients receiving oral SERDs.
Edward B. Garon, MD, MS - A Case of Best Practices: Optimizing First-Line Chemoimmunotherapy for Advanced Squamous NSCLC

Edward B. Garon, MD, MS - A Case of Best Practices: Optimizing First-Line Chemoimmunotherapy for Advanced Squamous NSCLC

2025-11-0319:09

Please visit answersincme.com/SAM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the importance of molecular testing in the treatment of advanced squamous NSCLC with immunotherapy. Upon completion of this activity, participants should be better able to: Assess the role of molecular testing in guiding first-line treatment selection for patients with advanced squamous non–small-cell lung cancer (NSCLC); Review the practical implications of the clinical evidence evaluating preferred combination immunotherapy regimens for the initial management of advanced squamous NSCLC; and Outline clinical, evidence-based strategies to optimize the provision of long-term care for patients with advanced squamous NSCLC receiving combination immunotherapy regimens.
Yasha Modi, MD - Putting Evidence Into Practice: Case-Based Strategies for Long-Acting Anti-VEGF Agents in nAMD

Yasha Modi, MD - Putting Evidence Into Practice: Case-Based Strategies for Long-Acting Anti-VEGF Agents in nAMD

2025-10-3113:16

Please visit answersincme.com/CED860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neovascular age-related macular degeneration (nAMD) discusses practical strategies to enhance the clinical implementation of long-acting anti-VEGF therapy. Upon completion of this activity, participants should be better able to: Select the optimal long-acting anti–vascular endothelial growth factor (VEGF) therapy for individual patients with neovascular age-related macular degeneration (nAMD); Integrate practical strategies to enhance the clinical implementation of long-acting anti-VEGF therapy in patients with nAMD; and Outline patient-centered strategies to facilitate adherence to anti-VEGF therapy.
Luis Paz-Ares, MD, PhD / Kristin Higgins, MD - Creating a Roadmap to Optimize Care for Patients With LS-SCLC: Integrating the Evidence Into Practical Care

Luis Paz-Ares, MD, PhD / Kristin Higgins, MD - Creating a Roadmap to Optimize Care for Patients With LS-SCLC: Integrating the Evidence Into Practical Care

2025-10-3031:21

Please visit answersincme.com/860/97851223-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the growing importance of immunotherapy in the management of limited-stage small-cell lung cancer (LS-SCLC). Upon completion of this activity, participants should be better able to: Review the clinical impact of immunotherapy-based regimens for the management of small-cell lung cancer (SCLC); and Identify clinical factors that drive treatment decision-making for patients with SCLC.
Charles L. Daley, MD / David E. Griffith, MD - Staying on Track with MAC Lung Disease Care: From Accurate Diagnosis to Evolving Management Strategies

Charles L. Daley, MD / David E. Griffith, MD - Staying on Track with MAC Lung Disease Care: From Accurate Diagnosis to Evolving Management Strategies

2025-10-2801:02:39

Please visit answersincme.com/860/96036801-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss the latest in diagnosis and optimized management of Mycobacterium avium complex (MAC) lung disease. Upon completion of this activity, participants should be better able to: Describe strategies to assess suspected nontuberculous mycobacterial (NTM) lung disease; Review guideline-recommended treatment plans for Mycobacterium avium complex (MAC) lung disease; Explain the clinical significance of the latest evidence for emerging first-line therapies for MAC lung disease, in the context of current standard of care; and Outline best practices to enhance outcomes for patients with MAC lung disease, including those receiving approved or emerging first-line therapies.
MeiLan Han, MD, MS / Eddie Needham, MD, FAAFP / Valerie Chang - COPD Primary Care Playbook: Boosting Diagnosis, Treatment, and Therapy Escalation for Optimal Disease Control

MeiLan Han, MD, MS / Eddie Needham, MD, FAAFP / Valerie Chang - COPD Primary Care Playbook: Boosting Diagnosis, Treatment, and Therapy Escalation for Optimal Disease Control

2025-10-1701:06:01

Please visit answersincme.com/860/MED-RESP-03268-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, a family medicine physician and a pulmonologist discuss strategies for optimizing chronic obstructive pulmonary disease (COPD) detection and management in primary care. Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations on the management of COPD; Identify the impact of approved follow-up pharmacotherapies in the treatment of COPD; and Determine personalized strategies to incorporate follow-up pharmacotherapies into clinical practice for COPD.
Jerry P. Abraham, MD MPH CMQ / Chuck Vega, MD- Primary Care Immunization Showdown: What Would You Do in These Complex Vaccine Scenarios?

Jerry P. Abraham, MD MPH CMQ / Chuck Vega, MD- Primary Care Immunization Showdown: What Would You Do in These Complex Vaccine Scenarios?

2025-10-1501:02:17

Please visit answersincme.com/860/CME-25-198904-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in infectious disease and family medicine discuss complex immunization needs of all patients, especially those with altered immunocompetence. Upon completion of this activity, participants should be better able to: Review how having altered immunocompetence affects response to vaccines; Apply the national guideline recommendations for immunization in individuals with altered immunocompetence; and Formulate effective communication strategies to enhance vaccine uptake in individuals with altered immunocompetence.
Andrew M. Brunner, MD - FLT3 Inhibitors in Action: Clinical Case Challenges in Newly Diagnosed AML

Andrew M. Brunner, MD - FLT3 Inhibitors in Action: Clinical Case Challenges in Newly Diagnosed AML

2025-10-0321:30

Please visit answersincme.com/MPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myelodysplastic syndromes discusses strategies for the management of FLT3-mutated acute myeloid leukemia. Upon completion of this activity, participants should be better able to: Summarize guideline recommendations for the treatment of newly diagnosed, FLT3-mutated acute myeloid leukemia (AML); Recognize the clinical significance of the evidence for approved FLT3 inhibitors in the first-line treatment of newly diagnosed, FLT3-mutated AML; Formulate strategies to maximize the impact of FLT3 inhibitors in the management of patients with newly-diagnosed, FLT3-mutated AML.
Lisa Larkin, MD, FACP, MSCP, IF - Advancing Menopause Management: Integrating Neurokinin-Targeted Therapies for Vasomotor Symptoms

Lisa Larkin, MD, FACP, MSCP, IF - Advancing Menopause Management: Integrating Neurokinin-Targeted Therapies for Vasomotor Symptoms

2025-10-0115:56

Please visit answersincme.com/VYT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in women’s health discusses the management of vasomotor symptoms (VMS) associated with menopause. Upon completion of this activity, participants should be better able to: Identify VMS as a consequence of menopause; Evaluate the efficacy and safety of new and emerging neurokinin (NK)-targeted therapies for VMS; Implement shared decision-making for optimal VMS treatment outcomes
Ramez N. Eskander, MD - Selecting the Optimal Regimen for Advanced Endometrial Cancer: A Case-Based, Multidisciplinary Approach

Ramez N. Eskander, MD - Selecting the Optimal Regimen for Advanced Endometrial Cancer: A Case-Based, Multidisciplinary Approach

2025-09-3019:38

Please visit answersincme.com/UDT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic oncology discusses primary chemoimmunotherapy regimens in advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Apply biomarker testing results to guide initial treatment decisions in advanced endometrial cancer; Select the optimal therapy for a given patient with endometrial cancer, based on the latest evidence; Design patient-centered, multidisciplinary care plans that support treatment continuity and patient survivorship.
loading
Comments 
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States